Texas Accused of Ignoring FDA on Stem Cell Rules
By Todd Ackerman,
Houston Chronicle
| 04. 10. 2012
Texas’ proposed adult stem cell regulations, up for approval this week, are under fire for circumventing the Food and Drug Administration and making the experimental therapy commercially available before it’s been proven safe and effective.
The criticism of the Texas Medical Board draft policy, developed in the aftermath of Gov. Rick Perry receiving stem cell treatment for back problems, is coming from a host of pre-eminent scientists and institutions, including the influential scientific journal Nature and the International Society for Stem Cell Research.
“Texas officials should take the FDA’s regulatory power over stem cells more seriously,” Nature said in an editorial. “If the medical board were to act according to its stated pledge to protect patients, then it would make clear the need for clinical validation of adult stem cells before use and rescind the medical licenses of any doctors in breach of rules about using unapproved treatments.”
Dr. Irving Weissman of the ISSCR called the draft “a clever way around the FDA’s appropriate role overseeing clinical trials.” Weissman, director of Stanford University’s Institute for Stem Cell Biology and Regenerative...
Related Articles
By Evelina Johansson Wilén, Jacobin | 01.18.2026
In her book The Argonauts, Maggie Nelson describes pregnancy as an experience marked by a peculiar duality. On the one hand, it is deeply transformative, bodily alien, sometimes almost incomprehensible to the person undergoing it. On the other hand...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By Paula Siverino Bavio, BioNews | 01.12.2026
For more than ten years, gestational surrogacy in Uruguay existed in a state of legal latency: provided for by law, carefully regulated as an exception, yet without a single birth to make it real.
That situation changed with the arrival...